CRESCENT BIOPHARMA, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
CRESCENT BIOPHARMA, INC. (CBIO) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 9.31 million shares for the 3-month period ending 2013-03-31, per its 10-Q filed 2014-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2015-03-16
- CRESCENT BIOPHARMA, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2013-03-31 was 9.31M shares.
- CRESCENT BIOPHARMA, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2012 was 9.31M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month |
|---|---|---|
| 2013-03-31 | 9.31M shares 10-Q · filed 2014-05-09 | |
| 2012-12-31 | 9.31M shares 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |